San Francisco, CA – December 10, 2009
DecisionView Inc., a provider of software solutions to optimize clinical trial enrollment for life sciences companies, today announced the release of StudyOptimizer™ 4, the latest iteration of its Web-based solution. DecisionView’s flagship product now includes advanced historical analysis and templates capabilities, as well as enhancements to its predictive analytics technology.
StudyOptimizer allows clinical trial managers to plan, track, diagnose, and correct enrollment plans via a single centralized Web-based application that
captures clinical trial patient enrollment data from across the organization. The application uses predictive analytics to forecast enrollment trends and estimate completion dates, which are updated based on actual enrollment patterns giving clinical trial managers information to measure actual and projected performance against plan.
“The ability to capture, analyze, and leverage historical clinical trial enrollment data in planning future patient recruitment efforts provides a critical baseline that life sciences organizations need in order to benchmark and improve these processes,” said said Alan Louie, Ph.D., Research Director, IDC.
Recently, DecisionView announced the availability of the Software-as-a-Service (SaaS) version of StudyOptimizer.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.